Peng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peng Chen has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Fuzhong Liu
Cancer Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China
3 shared publicationsKailing Li
Department of Urology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China
3 shared publicationsTing Pan
Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
3 shared publicationsXing Bi
Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
3 shared publicationsFuerhaiti Shayiti
Department of Urology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, China
2 shared publicationsHongbo Chen
Department of Urology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
2 shared publications
Latest Publications
- Open Access
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 43171
LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is characterized by abundant infiltration of CD8⁺ T cells; however, the clinical benefit from immune checkpoint inhibitors (ICI) remains limited. To clarify this paradox, we systematically investigated the functional states of CD8⁺ T cells in ccRCC, with a particular focus on exhaustion-associated subsets and their potential link to ICI responsiveness. By integrating six publicly available bulk and single-cell RNA sequencing datasets with independent institutional validation cohorts, we found that the majority of tumor-infiltrating CD8⁺ T cells exhibited an exhausted phenotype, characterized by elevated expression of canonical exhaustion markers. Importantly, we identified CD8⁺ T cells with high LIM domain-containing protein 2 (LIMD2) expression that co-express canonical exhaustion markers and are enriched in ICI responders. Single-cell transcriptomic analyses further supported markedly increased LIMD2 expression within CD8⁺ Tex cells from patients achieving clinical benefit. Multiplex immunofluorescence showed LIMD2 protein predominantly localized to CD8A⁺ T cells, co-expressed with exhaustion markers, and significantly enriched in tumor tissues of responders. Collectively, these findings indicate that CD8⁺ Tex cells with high LIMD2 expression are associated with ICI responses in ccRCC, positioning LIMD2 as a candidate predictive biomarker to refine patient stratification and inform immunotherapy optimization.
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 43171
Open AccessLIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is characterized by abundant infiltration of CD8⁺ T cells; however, the clinical benefit from immune checkpoint inhibitors (ICI) remains limited. To clarify this paradox, we systematically investigated the functional states of CD8⁺ T cells in ccRCC, with a particular focus on exhaustion-associated subsets and their potential link to ICI responsiveness. By integrating six publicly available bulk and single-cell RNA sequencing datasets with independent institutional validation cohorts, we found that the majority of tumor-infiltrating CD8⁺ T cells exhibited an exhausted phenotype, characterized by elevated expression of canonical exhaustion markers. Importantly, we identified CD8⁺ T cells with high LIM domain-containing protein 2 (LIMD2) expression that co-express canonical exhaustion markers and are enriched in ICI responders. Single-cell transcriptomic analyses further supported markedly increased LIMD2 expression within CD8⁺ Tex cells from patients achieving clinical benefit. Multiplex immunofluorescence showed LIMD2 protein predominantly localized to CD8A⁺ T cells, co-expressed with exhaustion markers, and significantly enriched in tumor tissues of responders. Collectively, these findings indicate that CD8⁺ Tex cells with high LIMD2 expression are associated with ICI responses in ccRCC, positioning LIMD2 as a candidate predictive biomarker to refine patient stratification and inform immunotherapy optimization.
- Open Access
- 30 December 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-17
Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC
Immune checkpoint inhibitors (ICIs) are a cornerstone therapy for advanced renal cell carcinoma (RCC). However, significant rates of primary resistance hinder their efficacy, and the underlying mechanisms remain poorly understood. This study aims to unravel the tumor-immune interactions and signaling pathways driving primary resistance to ICIs in RCC. We integrated single-cell RNA sequencing, spatial transcriptomics, and clinical sample analysis to investigate the tumor microenvironment and intercellular signaling. Advanced computational methods, including cell–cell communication networks, pseudotime trajectories, and gene set enrichment analysis (GSEA), were employed to uncover the underlying resistance mechanisms. Compared to the sensitive group, the primary resistance group exhibited a significant increase in SPP1-CD44 signaling-mediated interactions between tumor cells and immune cells. These interactions disrupted antigen presentation in immune effector cells and suppressed key chemokine and cytokine pathways, thereby impairing effective immune responses. In contrast, the sensitive group showed more active antigen presentation and cytokine signaling, which facilitated stronger immune responses. Furthermore, the interaction between SPP1-secreting tumor cells and CD44-expressing exhausted CD8 + T cells activated the MAPK signaling pathway within CD8 + Tex cells, exacerbating T cell exhaustion and driving the development of ICI resistance in RCC. Our findings reveal a potential mechanism by which SPP1-CD44 signaling mediates tumor-immune cell interactions leading to ICI resistance, providing a theoretical basis for targeting and disrupting this signaling to overcome primary resistance in RCC.
- 30 December 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-17
Open AccessSingle-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC
Immune checkpoint inhibitors (ICIs) are a cornerstone therapy for advanced renal cell carcinoma (RCC). However, significant rates of primary resistance hinder their efficacy, and the underlying mechanisms remain poorly understood. This study aims to unravel the tumor-immune interactions and signaling pathways driving primary resistance to ICIs in RCC. We integrated single-cell RNA sequencing, spatial transcriptomics, and clinical sample analysis to investigate the tumor microenvironment and intercellular signaling. Advanced computational methods, including cell–cell communication networks, pseudotime trajectories, and gene set enrichment analysis (GSEA), were employed to uncover the underlying resistance mechanisms. Compared to the sensitive group, the primary resistance group exhibited a significant increase in SPP1-CD44 signaling-mediated interactions between tumor cells and immune cells. These interactions disrupted antigen presentation in immune effector cells and suppressed key chemokine and cytokine pathways, thereby impairing effective immune responses. In contrast, the sensitive group showed more active antigen presentation and cytokine signaling, which facilitated stronger immune responses. Furthermore, the interaction between SPP1-secreting tumor cells and CD44-expressing exhausted CD8 + T cells activated the MAPK signaling pathway within CD8 + Tex cells, exacerbating T cell exhaustion and driving the development of ICI resistance in RCC. Our findings reveal a potential mechanism by which SPP1-CD44 signaling mediates tumor-immune cell interactions leading to ICI resistance, providing a theoretical basis for targeting and disrupting this signaling to overcome primary resistance in RCC.
- Open Access
- 8 January 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-18
Single-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma
Background: Aberrant intracellular or intercellular signaling pathways are important mechanisms that contribute to the development and progression of cancer. However, the intercellular communication associated with the development of ccRCC is currently unknown. The purpose of this study was to examine the aberrant tumor cell-to-cell communication signals during the development of ccRCC. Methods: We conducted an analysis on the scRNA-seq data of 6 ccRCC and 6 normal kidney tissues. This analysis included sub clustering, CNV analysis, single-cell trajectory analysis, cell–cell communication analysis, and transcription factor analysis. Moreover, we performed validation tests on clinical samples using multiplex immunofluorescence. Results: This study identified eleven aberrantly activated intercellular signaling pathways in tumor clusters from ccRCC samples. Among these, two of the majors signaling molecules, MIF and SPP1, were mainly secreted by a subpopulation of cancer stem cells. This subpopulation demonstrated high expression levels of the cancer stem cell markers POU5F1 and CD44 (POU5F1hiCD44hiE.T), with the transcription factor POU5F1 regulating the expression of SPP1. Further research demonstrated that SPP1 binds to integrin receptors on the surface of target cells and promotes ccRCC development and progression by activating potential signaling mechanisms such as ILK and JAK/STAT. Conclusion: Aberrantly activated tumor intercellular signaling pathways promote the development and progression of ccRCC. The cancer stem cell subpopulation (POU5F1hiCD44hiE.T) promotes malignant transformation and the development of a malignant phenotype by releasing aberrant signaling molecules and interacting with other tumor cells.
- 8 January 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-18
Open AccessSingle-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma
Background: Aberrant intracellular or intercellular signaling pathways are important mechanisms that contribute to the development and progression of cancer. However, the intercellular communication associated with the development of ccRCC is currently unknown. The purpose of this study was to examine the aberrant tumor cell-to-cell communication signals during the development of ccRCC. Methods: We conducted an analysis on the scRNA-seq data of 6 ccRCC and 6 normal kidney tissues. This analysis included sub clustering, CNV analysis, single-cell trajectory analysis, cell–cell communication analysis, and transcription factor analysis. Moreover, we performed validation tests on clinical samples using multiplex immunofluorescence. Results: This study identified eleven aberrantly activated intercellular signaling pathways in tumor clusters from ccRCC samples. Among these, two of the majors signaling molecules, MIF and SPP1, were mainly secreted by a subpopulation of cancer stem cells. This subpopulation demonstrated high expression levels of the cancer stem cell markers POU5F1 and CD44 (POU5F1hiCD44hiE.T), with the transcription factor POU5F1 regulating the expression of SPP1. Further research demonstrated that SPP1 binds to integrin receptors on the surface of target cells and promotes ccRCC development and progression by activating potential signaling mechanisms such as ILK and JAK/STAT. Conclusion: Aberrantly activated tumor intercellular signaling pathways promote the development and progression of ccRCC. The cancer stem cell subpopulation (POU5F1hiCD44hiE.T) promotes malignant transformation and the development of a malignant phenotype by releasing aberrant signaling molecules and interacting with other tumor cells.
- Open Access
- 18 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Retrospective analysis of urinary tract stone composition in a Chinese ethnic minority colony based on Fourier transform infrared spectroscopy
To analyze the relationship between the composition of urinary stones and various influencing factors in the Enshi region. We used FT-IR to examine the composition of 1092 stone samples. Combined with the relevant clinical materials, the data were analyzed using both one-dimensional statistical methods and multivariate statistical methods. The study included 1092 stone samples, classified as follows: 457 (41.8%) with a single component, 453 (41.5%) with two components, 149 (13.6%) with three components, and 33 (3.0%) with four components. Stones were categorized into five types: Calcium Oxalate (CaOx) (76.4%), carbapatite (CaP) (9.3%), Struvite (ST) (8.3%), Uric Acid (UA) (4.9%), and Others (1.0%). Age, gender, urinary tract infection (UTI), family history of urinary stones (FH), hyperuricemia (HUA) and stone location were significantly associated with stone type. Logistic regression revealed that females and UTI were relative risk factors for predicting CaP and ST, while FH and HUA were relative risk factors for predicting UA. Our study indicates that the overall composition of urinary tract stones in the Enshi region is consistent with that of the entire China. Additionally, the predisposing factors for stone formation vary in terms of gender, age, FH, UTI, hyperuricemia HUA, and stone location.
- 18 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Open AccessRetrospective analysis of urinary tract stone composition in a Chinese ethnic minority colony based on Fourier transform infrared spectroscopy
To analyze the relationship between the composition of urinary stones and various influencing factors in the Enshi region. We used FT-IR to examine the composition of 1092 stone samples. Combined with the relevant clinical materials, the data were analyzed using both one-dimensional statistical methods and multivariate statistical methods. The study included 1092 stone samples, classified as follows: 457 (41.8%) with a single component, 453 (41.5%) with two components, 149 (13.6%) with three components, and 33 (3.0%) with four components. Stones were categorized into five types: Calcium Oxalate (CaOx) (76.4%), carbapatite (CaP) (9.3%), Struvite (ST) (8.3%), Uric Acid (UA) (4.9%), and Others (1.0%). Age, gender, urinary tract infection (UTI), family history of urinary stones (FH), hyperuricemia (HUA) and stone location were significantly associated with stone type. Logistic regression revealed that females and UTI were relative risk factors for predicting CaP and ST, while FH and HUA were relative risk factors for predicting UA. Our study indicates that the overall composition of urinary tract stones in the Enshi region is consistent with that of the entire China. Additionally, the predisposing factors for stone formation vary in terms of gender, age, FH, UTI, hyperuricemia HUA, and stone location.
- 18 May 2021
- Published by Wiley in Cell Biology International
- Vol. 45 (10) , 2054-2062
Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer
The crosstalk between tumor microenvironment and cancer cells is emerging as a critical determinant in tumor progression. However, the underlying mechanism of tumor microenvironment‐induced cancer development remains controversial. Here, our study provides evidence to suggest that tumor‐associated macrophage (TAM) enrichment is found in chemoresistant prostatic tumor tissues. Those TAMs are demonstrated to promote chemoresistance and distant metastasis in prostatic cancer through secretion of CCL5. Mechanistically, TAM coculture or additional CCL5 can mediate the STAT3‐dependent epithelial–mesenchymal transition process, resulting in distant metastasis in prostatic cancer. Meanwhile, activation of STAT3 induced by CCL5 can mediate upregulation of the transcription factor Nanog, leading to drug resistance. In vivo study further demonstrated that blockade of STAT3 signals significantly reverses chemoresistance and suppresses lung metastasis in colorectal tumor‐bearing mice, suggesting a novel strategy for clinical prostatic cancer treatment.
- 18 May 2021
- Published by Wiley in Cell Biology International
- Vol. 45 (10) , 2054-2062
Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer
The crosstalk between tumor microenvironment and cancer cells is emerging as a critical determinant in tumor progression. However, the underlying mechanism of tumor microenvironment‐induced cancer development remains controversial. Here, our study provides evidence to suggest that tumor‐associated macrophage (TAM) enrichment is found in chemoresistant prostatic tumor tissues. Those TAMs are demonstrated to promote chemoresistance and distant metastasis in prostatic cancer through secretion of CCL5. Mechanistically, TAM coculture or additional CCL5 can mediate the STAT3‐dependent epithelial–mesenchymal transition process, resulting in distant metastasis in prostatic cancer. Meanwhile, activation of STAT3 induced by CCL5 can mediate upregulation of the transcription factor Nanog, leading to drug resistance. In vivo study further demonstrated that blockade of STAT3 signals significantly reverses chemoresistance and suppresses lung metastasis in colorectal tumor‐bearing mice, suggesting a novel strategy for clinical prostatic cancer treatment.
- Open Access
- 23 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 1-10
A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer
Background: The 8th American Joint Committee on Cancer tumor–node–metastasis (AJCC‐TNM) staging system is based on a few retrospective single‐center studies. We aimed to test the prognostic validity of the staging system and to determine whether a modified clinicopathological tumor staging system that includes lymphovascular embolization could increase the accuracy of prognostic prediction for patients with stage T2–3 penile cancer. Methods: A training cohort of 411 patients who were treated at 2 centers in China and Brazil between 2000 and 2015 were staged according to the 8th AJCC‐TNM staging system. The internal validation was analyzed by bootstrap‐corrected C‐indexes (resampled 1000 times). Data from 436 patients who were treated at 15 centers over four continents were used for external validation. Results: A survivorship overlap was observed between T2 and T3 patients ( P = 0.587) classified according to the 8th AJCC‐TNM staging system. Lymphovascular embolization was a significant prognostic factor for metastasis and survival (all P < 0.001). Based on the multivariate analysis, only lymphovascular embolization showed a significant influence on cancer‐specific survival (CSS) (hazard ratio = 1.587, 95% confidence interval = 1.253–2.011; P = 0.001). T2 and T3 patients with lymphovascular embolization showed significantly shorter CSS than did those without lymphovascular embolization ( P < 0.001). Therefore, a modified clinicopathological staging system was proposed, with the T2 and T3 categories of the 8th AJCC‐TNM staging system being subdivided into two new categories as follows: t2 tumors invade the corpus spongiosum and/or corpora cavernosa and/or urethra without lymphovascular invasion, and t3 tumors invade the corpus spongiosum and/or corpora cavernosa and/or urethra with lymphovascular invasion. The modified staging system involving lymphovascular embolization showed improved prognostic stratification with significant differences in CSS among all categories (all P < 0.005) and exhibited higher accuracy in predicting patient prognoses than did the 8th AJCC‐TNM staging system (C‐index, 0.739 vs. 0.696). These results were confirmed in the external validation cohort. Conclusions: T2–3 penile cancers are heterogeneous, and a modified clinicopathological staging system that incorporates lymphovascular embolization may better predict the prognosis of patients with penile cancer than does the 8th AJCC‐TNM staging system. Trial registration This study was retrospectively registered on Chinese Clinical Trail Registry: ChiCTR16008041 (2016‐03‐02). http://www.chictr.org.cn
- 23 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 1-10
Open AccessA modified clinicopathological tumor staging system for survival prediction of patients with penile cancer
Background: The 8th American Joint Committee on Cancer tumor–node–metastasis (AJCC‐TNM) staging system is based on a few retrospective single‐center studies. We aimed to test the prognostic validity of the staging system and to determine whether a modified clinicopathological tumor staging system that includes lymphovascular embolization could increase the accuracy of prognostic prediction for patients with stage T2–3 penile cancer. Methods: A training cohort of 411 patients who were treated at 2 centers in China and Brazil between 2000 and 2015 were staged according to the 8th AJCC‐TNM staging system. The internal validation was analyzed by bootstrap‐corrected C‐indexes (resampled 1000 times). Data from 436 patients who were treated at 15 centers over four continents were used for external validation. Results: A survivorship overlap was observed between T2 and T3 patients ( P = 0.587) classified according to the 8th AJCC‐TNM staging system. Lymphovascular embolization was a significant prognostic factor for metastasis and survival (all P < 0.001). Based on the multivariate analysis, only lymphovascular embolization showed a significant influence on cancer‐specific survival (CSS) (hazard ratio = 1.587, 95% confidence interval = 1.253–2.011; P = 0.001). T2 and T3 patients with lymphovascular embolization showed significantly shorter CSS than did those without lymphovascular embolization ( P < 0.001). Therefore, a modified clinicopathological staging system was proposed, with the T2 and T3 categories of the 8th AJCC‐TNM staging system being subdivided into two new categories as follows: t2 tumors invade the corpus spongiosum and/or corpora cavernosa and/or urethra without lymphovascular invasion, and t3 tumors invade the corpus spongiosum and/or corpora cavernosa and/or urethra with lymphovascular invasion. The modified staging system involving lymphovascular embolization showed improved prognostic stratification with significant differences in CSS among all categories (all P < 0.005) and exhibited higher accuracy in predicting patient prognoses than did the 8th AJCC‐TNM staging system (C‐index, 0.739 vs. 0.696). These results were confirmed in the external validation cohort. Conclusions: T2–3 penile cancers are heterogeneous, and a modified clinicopathological staging system that incorporates lymphovascular embolization may better predict the prognosis of patients with penile cancer than does the 8th AJCC‐TNM staging system. Trial registration This study was retrospectively registered on Chinese Clinical Trail Registry: ChiCTR16008041 (2016‐03‐02). http://www.chictr.org.cn